A study from Brown University reveals the Shingrix vaccine, developed to guard against shingles, reduces dementia risk by 24%. Among nearly 510,000 nursing facility residents, 18.8% who received the vaccine developed dementia versus 24.6% of those unvaccinated.
Pharmacoepidemiologist Kaley Hayes emphasizes the protective benefits of Shingrix, which has replaced the older Zostavax due to its greater efficacy. Despite a low vaccination uptake during the study period, the evidence suggests that one in 17 dementia cases could potentially be prevented through vaccination.
Limitations of the observational study include uncertainties about direct cause and effect and potential biases in vaccine uptake. Future research aims to clarify the mechanisms behind these findings, particularly the link between shingles infections and neuroinflammation.
The CDC recommends shingles vaccinations for adults over 50, highlighting the growing importance of immunization not only for physical health but cognitive well-being as well.